Drug Profile
Research programme: schizophrenia therapeutic - QLT USA
Alternative Names: Atrigel® risperidone; Risperidone implant - QLT USA; Sustained release risperidone - QLT USALatest Information Update: 11 Nov 2009
Price :
$50
*
At a glance
- Originator QLT USA
- Class Pyrimidinones
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 22 Nov 2004 Atrix Laboratories has been acquired by QLT
- 11 Aug 2004 Preclinical trials in Schizophrenia in USA (Injection)